Summit Therapeutics Secures $200 Million Investment from Top Biotech Hedge Fund
05 Jun 2024
In a significant boost, Summit Therapeutics, a clinical-stage biopharmaceutical company, has announced a $200 million investment from the renowned Baker Brothers Advisors hedge fund. The investment, at $9 per share, will help propel the clinical development of Summit's lead asset, ivonescimab (AK112), a PD-1/VEGF bispecific antibody being co-developed with Chinese company Akeso Biopharma.
Baker Brothers Advisors, founded by brothers Julian and Felix Baker, is one of the top biotech-focused hedge funds in the U.S., managing over $20 billion in assets. Known for its impressive long-term performance, the fund has been a major investor in several successful biotech companies over the years, including Incyte and BeiGene.
This latest investment makes Summit Therapeutics the ninth largest holding in the Baker Brothers portfolio, underscoring the fund's confidence in the potential of ivonescimab. The funds will be used to advance the clinical development of ivonescimab, as well as for general corporate purposes.
The investment comes at a critical time for Summit, as its partner Akeso Biopharma recently announced both positive and negative data for ivonescimab. While the drug showed promising results in a head-to-head trial against pembrolizumab, it failed to demonstrate superiority over the combination of bevacizumab, sintilimab, and chemotherapy in non-small cell lung cancer patients with EGFR-TKI resistance.
Despite these mixed results, the new funding from Baker Brothers, along with the expanded global licensing agreement between Summit and Kangmei, suggest that the companies remain optimistic about the future of ivonescimab. The drug's potential to target both the PD-1 and VEGF pathways simultaneously could give it a competitive edge in the crowded immunotherapy landscape.
As Summit Therapeutics works to advance ivonescimab's clinical development, this substantial investment from a renowned biotech investor like Baker Brothers is a strong vote of confidence in the company's pipeline and future prospects.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.